Fenebrutinib for children with relapsing MS
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests a new oral medication called fenebrutinib for children and teenagers with relapsing multiple sclerosis. It aims to find the right dose and see how safe and effective it is compared to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or younger and diagnosed with relapsing multiple sclerosis (RMS).
- You must have had at least one MS relapse in the past year (or two in the past two years), or a recent brain scan showing active inflammation.
- Your disability level should be mild to moderate (score of 0 to 5.5 on a standard disability scale).
- You must be up to date on all recommended childhood vaccinations.
- You cannot have other serious conditions like cancer, bleeding problems, active infections, or certain mental health issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ublituximab to see if it can reduce flare-ups in children and teens who have relapsing multiple sclerosis. It aims to understand if the treatment is safe and effective for younger patients.
This study tests a new oral medication called remibrutinib for people with relapsing multiple sclerosis who are currently on Ocrevus. Participants will switch from Ocrevus to remibrutinib to see if it is safe and effective.
This study tests an oral medication, dimethyl fumarate, which is already used for multiple sclerosis. It aims to see how well it controls relapses in people with relapsing forms of MS. If you have had a relapse in the last year, you might be eligible.
This study tests a new oral medication called Rocbrutinib for people with relapsing-remitting multiple sclerosis (RRMS). The drug targets a protein that may help reduce the immune system's attack on the brain and spinal cord. The trial will check if the medication can reduce new brain lesions and slow down disability progression.
This study tests an experimental pill called remibrutinib in people with multiple sclerosis (MS). It uses MRI scans to see how well the drug works at reducing MS activity. This could help people with relapsing or progressive MS.
This study tests two oral medications, diroximel fumarate and dimethyl fumarate, in children and teens with relapsing MS. It aims to see if they are safe and can reduce the number of relapses compared to each other.
Hear when a new Relapsing Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.